Sentiment-Signal
12,8
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 20.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Definitive Agreement. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce |
| 13.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 28.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 29.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Securities. The disclosure contained in Item 5.02 of this Current Report on Form 8-K regarding the issuance of an indu |
| 13.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C |
Stammdaten
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Unternehmen & Branche
| Name | Rezolute, Inc. |
|---|---|
| Ticker | RZLT |
| CIK | 0001509261 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 296,6 Mio. USD |
| Beta | 0,66 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | -22,774,000 | -0.22 | 138,629,000 | 127,998,000 | |
| 2025-09-30 | 10-Q | -18,150,000 | -0.18 | 158,664,000 | 147,168,000 | |
| 2025-06-30 | 10-K | -74,412,000 | -0.98 | 175,490,000 | 162,127,000 | |
| 2025-06-30 | 10-Q | -74,400,000 | 175,490,000 | 162,127,000 | ||
| 2025-03-31 | 10-Q | -18,914,000 | -0.27 | 94,739,000 | 82,569,000 | |
| 2024-12-31 | 10-Q | -15,730,000 | -0.22 | 112,007,000 | 99,589,000 | |
| 2024-09-30 | 10-Q | -15,378,000 | -0.22 | 123,414,000 | 113,441,000 | |
| 2024-06-30 | 10-Q | -68,500,000 | 132,737,000 | 121,003,000 | ||
| 2024-06-30 | 10-K | -68,459,000 | -1.33 | 132,737,000 | 121,003,000 | |
| 2024-03-31 | 10-Q | -17,050,000 | -0.34 | 87,737,000 | 70,861,000 | |
| 2023-12-31 | 10-Q | -13,909,000 | -0.27 | 102,150,000 | 91,728,000 | |
| 2023-09-30 | 10-Q | -14,524,000 | -0.28 | 112,999,000 | 103,564,000 | |
| 2023-06-30 | 10-K | -51,787,000 | -1.01 | 123,721,000 | 116,172,000 | |
| 2023-06-30 | 10-Q | -51,800,000 | 123,721,000 | 116,172,000 | ||
| 2023-03-31 | 10-Q | -15,672,000 | -0.30 | 134,205,000 | 127,316,000 | |
| 2022-12-31 | 10-Q | -13,556,000 | -0.26 | 150,208,000 | 141,265,000 | |
| 2022-09-30 | 10-Q | -9,831,000 | -0.19 | 155,988,000 | 153,090,000 | |
| 2022-06-30 | 10-Q | -41,100,000 | 152,420,000 | 149,471,000 | ||
| 2022-06-30 | 10-K | -41,060,000 | -2.32 | 152,420,000 | 149,471,000 | |
| 2022-03-31 | 10-Q | -11,208,000 | -0.65 | 69,573,000 | 51,907,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-16 | ROBERTS BRIAN KENNETH | Officer, Chief Medical Officer | Open Market Purchase | 28,000 | 1.70 | 47,600.00 | +14,4% | |
| 2025-12-16 | Hogenhuis Wladimir | Director | Open Market Purchase | 5,650 | 1.69 | 9,548.50 | +2,9% | |
| 2025-12-15 | Evans Daron | Officer, CFO | Open Market Purchase | 2,500 | 1.79 | 4,475.00 | +1,4% | |
| 2025-12-15 | Evans Daron | Officer, CFO | Open Market Purchase | 2,500 | 1.79 | 4,462.50 | +1,3% | |
| 2025-12-15 | Evans Daron | Officer, CFO | Open Market Purchase | 40,000 | 1.77 | 70,640.00 | +21,3% | |
| 2025-12-15 | Elam Nevan C | Director, Officer, CEO | Open Market Purchase | 32,000 | 1.59 | 50,880.00 | +15,4% | |
| 2025-12-15 | Karnawat Sunil Ratilal | Officer, Chief Commercial Officer | Open Market Purchase | 100 | 1.60 | 160.00 | 0,0% | |
| 2025-12-15 | Karnawat Sunil Ratilal | Officer, Chief Commercial Officer | Open Market Purchase | 12,000 | 1.62 | 19,438.80 | +5,9% | |
| 2025-12-09 | Evans Daron | Officer, CFO | Open Market Purchase | 10,549 | 5.04 | 53,166.96 | +16,1% | |
| 2025-06-25 | ROBERTS BRIAN KENNETH | Officer, Chief Medical Officer | Open Market Purchase | 2,500 | 4.38 | 10,939.00 | +3,3% | |
| 2025-06-24 | Evans Daron | Officer, CFO | Open Market Purchase | 5,000 | 4.05 | 20,250.00 | +6,1% | |
| 2025-06-13 | KREHER NERISSA | Director | Open Market Purchase | 3,076 | 3.25 | 9,997.00 | +3,0% | |
| 2025-06-13 | Kim Young-Jin | Director | Open Market Purchase | 1,230,769 | 3.25 | 3,999,999.25 | +1208,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.